Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases

Ferga C. Gleeson, Benjamin R. Kipp, Michael J. Levy, Jesse S. Voss, Michael B. Campion, Douglas M. Minot, Zheng J. Tu, Eric W Klee, Konstantinos N Lazaridis, Sarah E. Kerr

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Somatic serine/threonine kinase 11 (STK11) also known as liver kinase B1 (LKB1) is a tumor suppressor gene and ranks as the third most frequently mutated gene in lung adenocarcinoma. However, current molecular testing guidelines recommend evaluating for epidermal growth factor receptor mutations and ALK fusions to guide therapy in all patients with advanced stage adenocarcinoma, regardless of gender, race, or smoking history. Identifying alternative "driver" mutations and using actionable targeted pharmacotherapy is a key approach to providing effective individualized medical care. The analytical sensitivity and parallel multigene approach of targeted next-generation sequencing is an attractive methodology for use for cytology specimens. The presented lung adenocarcinoma study revealed that STK11 mutations alone and concomitant KRAS/STK11 mutations were identified in 18.2% and 4.5% of solitary adrenal metastases, respectively. Molecular profiling of epidermal growth factor receptor tyrosine kinase inhibitor resistant tumors may help to identify patients who would most benefit from alternative single or dual pathway inhibition potentially leading to a revision in current molecular testing guidelines.

Original languageEnglish (US)
Pages (from-to)531-534
Number of pages4
JournalJournal of Thoracic Oncology
Volume10
Issue number3
DOIs
StatePublished - Mar 30 2015

Fingerprint

Protein-Serine-Threonine Kinases
Neoplasm Metastasis
Mutation
Epidermal Growth Factor Receptor
Guidelines
Tumor Suppressor Genes
Protein-Tyrosine Kinases
Cell Biology
Adenocarcinoma
Phosphotransferases
Smoking
History
Drug Therapy
Adenocarcinoma of lung
Liver
Genes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Gleeson, F. C., Kipp, B. R., Levy, M. J., Voss, J. S., Campion, M. B., Minot, D. M., ... Kerr, S. E. (2015). Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. Journal of Thoracic Oncology, 10(3), 531-534. https://doi.org/10.1097/JTO.0000000000000391

Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. / Gleeson, Ferga C.; Kipp, Benjamin R.; Levy, Michael J.; Voss, Jesse S.; Campion, Michael B.; Minot, Douglas M.; Tu, Zheng J.; Klee, Eric W; Lazaridis, Konstantinos N; Kerr, Sarah E.

In: Journal of Thoracic Oncology, Vol. 10, No. 3, 30.03.2015, p. 531-534.

Research output: Contribution to journalArticle

Gleeson, Ferga C. ; Kipp, Benjamin R. ; Levy, Michael J. ; Voss, Jesse S. ; Campion, Michael B. ; Minot, Douglas M. ; Tu, Zheng J. ; Klee, Eric W ; Lazaridis, Konstantinos N ; Kerr, Sarah E. / Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. In: Journal of Thoracic Oncology. 2015 ; Vol. 10, No. 3. pp. 531-534.
@article{3f1711d190264b38a8c17e6988396179,
title = "Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases",
abstract = "Somatic serine/threonine kinase 11 (STK11) also known as liver kinase B1 (LKB1) is a tumor suppressor gene and ranks as the third most frequently mutated gene in lung adenocarcinoma. However, current molecular testing guidelines recommend evaluating for epidermal growth factor receptor mutations and ALK fusions to guide therapy in all patients with advanced stage adenocarcinoma, regardless of gender, race, or smoking history. Identifying alternative {"}driver{"} mutations and using actionable targeted pharmacotherapy is a key approach to providing effective individualized medical care. The analytical sensitivity and parallel multigene approach of targeted next-generation sequencing is an attractive methodology for use for cytology specimens. The presented lung adenocarcinoma study revealed that STK11 mutations alone and concomitant KRAS/STK11 mutations were identified in 18.2{\%} and 4.5{\%} of solitary adrenal metastases, respectively. Molecular profiling of epidermal growth factor receptor tyrosine kinase inhibitor resistant tumors may help to identify patients who would most benefit from alternative single or dual pathway inhibition potentially leading to a revision in current molecular testing guidelines.",
author = "Gleeson, {Ferga C.} and Kipp, {Benjamin R.} and Levy, {Michael J.} and Voss, {Jesse S.} and Campion, {Michael B.} and Minot, {Douglas M.} and Tu, {Zheng J.} and Klee, {Eric W} and Lazaridis, {Konstantinos N} and Kerr, {Sarah E.}",
year = "2015",
month = "3",
day = "30",
doi = "10.1097/JTO.0000000000000391",
language = "English (US)",
volume = "10",
pages = "531--534",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases

AU - Gleeson, Ferga C.

AU - Kipp, Benjamin R.

AU - Levy, Michael J.

AU - Voss, Jesse S.

AU - Campion, Michael B.

AU - Minot, Douglas M.

AU - Tu, Zheng J.

AU - Klee, Eric W

AU - Lazaridis, Konstantinos N

AU - Kerr, Sarah E.

PY - 2015/3/30

Y1 - 2015/3/30

N2 - Somatic serine/threonine kinase 11 (STK11) also known as liver kinase B1 (LKB1) is a tumor suppressor gene and ranks as the third most frequently mutated gene in lung adenocarcinoma. However, current molecular testing guidelines recommend evaluating for epidermal growth factor receptor mutations and ALK fusions to guide therapy in all patients with advanced stage adenocarcinoma, regardless of gender, race, or smoking history. Identifying alternative "driver" mutations and using actionable targeted pharmacotherapy is a key approach to providing effective individualized medical care. The analytical sensitivity and parallel multigene approach of targeted next-generation sequencing is an attractive methodology for use for cytology specimens. The presented lung adenocarcinoma study revealed that STK11 mutations alone and concomitant KRAS/STK11 mutations were identified in 18.2% and 4.5% of solitary adrenal metastases, respectively. Molecular profiling of epidermal growth factor receptor tyrosine kinase inhibitor resistant tumors may help to identify patients who would most benefit from alternative single or dual pathway inhibition potentially leading to a revision in current molecular testing guidelines.

AB - Somatic serine/threonine kinase 11 (STK11) also known as liver kinase B1 (LKB1) is a tumor suppressor gene and ranks as the third most frequently mutated gene in lung adenocarcinoma. However, current molecular testing guidelines recommend evaluating for epidermal growth factor receptor mutations and ALK fusions to guide therapy in all patients with advanced stage adenocarcinoma, regardless of gender, race, or smoking history. Identifying alternative "driver" mutations and using actionable targeted pharmacotherapy is a key approach to providing effective individualized medical care. The analytical sensitivity and parallel multigene approach of targeted next-generation sequencing is an attractive methodology for use for cytology specimens. The presented lung adenocarcinoma study revealed that STK11 mutations alone and concomitant KRAS/STK11 mutations were identified in 18.2% and 4.5% of solitary adrenal metastases, respectively. Molecular profiling of epidermal growth factor receptor tyrosine kinase inhibitor resistant tumors may help to identify patients who would most benefit from alternative single or dual pathway inhibition potentially leading to a revision in current molecular testing guidelines.

UR - http://www.scopus.com/inward/record.url?scp=84938266086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938266086&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000391

DO - 10.1097/JTO.0000000000000391

M3 - Article

C2 - 25695224

AN - SCOPUS:84938266086

VL - 10

SP - 531

EP - 534

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -